Free tool
Oncology stocks
We cover 86 companies grouped under the Oncology theme. The median market value in the group is $555.98M. Across the group, the median move over the past trading day is +2.48%. 67% of the 83 with a 200-day average trade above it. Price change over the past year runs from −24.6% to +240.8% across the middle 80 percent of the group, with a median of +42.5%. Across the group, 2 companies currently carry a tier A volume signal.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
86 of 319 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return |
|---|---|---|---|---|---|
| BMY | Bristol-Myers Squibb Company | $67.92 | +8.57% | +28.36% | +49.31% |
| RVMD | Revolution Medicines, Inc. | $211.38 | +12.39% | +167.50% | +492.60% |
| ONC | BeOne Medicines AG | $376.37 | +15.49% | +21.01% | +21.95% |
| BNTX | BioNTech SE | $114.05 | +25.21% | +17.95% | +8.55% |
| INCY | Incyte Corporation | $129.72 | +9.13% | +27.90% | +53.04% |
| GMAB | Genmab A/S | $34.36 | +19.31% | +7.98% | +41.34% |
| EXEL | Exelixis, Inc. | $56.72 | +1.63% | +30.15% | +49.66% |
| SMMT | Summit Therapeutics Inc. | $13.36 | +1.95% | −23.74% | −49.14% |
| ZYME | Zymeworks Inc. | $27.47 | +19.43% | +3.19% | +88.54% |
| IMCR | Immunocore Holdings plc | $37.40 | +10.75% | +10.72% | +14.76% |
| DMRA | Damora Therapeutics, Inc. | $30.62 | +4.01% | +40.33% | +800.59% |
| VIR | Vir Biotechnology, Inc. | $10.71 | +21.70% | +80.30% | +144.52% |
| INBX | Inhibrx Biosciences, Inc. | $122.72 | +48.84% | +63.54% | +390.10% |
| SNDX | Syndax Pharmaceuticals, Inc. | $19.92 | −2.92% | −6.48% | +27.20% |
| BCAX | Bicara Therapeutics Inc. | $24.58 | −11.61% | +50.06% | +117.14% |
| AAPG | Ascentage Pharma Group Internat | $16.79 | −11.12% | −36.33% | −61.38% |
| AVBP | ArriVent BioPharma, Inc. | $31.35 | +3.95% | +50.72% | +62.02% |
| REPL | Replimune Group, Inc. | $15.80 | +83.08% | +77.53% | +187.80% |
| AKTS | Aktis Oncology, Inc. | $26.69 | +10.24% | +19.15% | +19.15% |
| CGEM | Cullinan Therapeutics, Inc. | $22.95 | +31.67% | +126.78% | +200.39% |
| ORIC | ORIC Pharmaceuticals, Inc. | $13.83 | +15.06% | +69.28% | +43.76% |
| DRTS | Alpha Tau Medical Ltd. | $14.70 | +20.39% | +204.35% | +357.94% |
| IMTX | Immatics N.V. | $9.24 | +7.07% | −11.58% | +76.67% |
| GLUE | Monte Rosa Therapeutics, Inc. | $14.56 | −35.46% | −4.90% | +217.21% |
| CRVS | Corvus Pharmaceuticals, Inc. | $14.56 | +12.69% | +98.91% | +167.16% |
| JANX | Janux Therapeutics, Inc. | $18.68 | +19.97% | +36.85% | −18.82% |
| KURA | Kura Oncology, Inc. | $13.59 | +33.89% | +31.49% | +77.65% |
| CADL | Candel Therapeutics, Inc. | $13.60 | +36.55% | +150.00% | +138.18% |
| GERN | Geron Corporation | $1.55 | +4.73% | +17.42% | +9.15% |
| OLMA | Olema Pharmaceuticals, Inc. | $10.91 | −9.16% | −56.84% | +95.17% |
| ANL | Adlai Nortye Ltd. | $13.74 | +13.93% | +895.65% | +737.80% |
| RIGL | Rigel Pharmaceuticals, Inc. | $46.75 | +25.03% | +11.76% | +14.75% |
| AURA | Aura Biosciences, Inc. | $7.82 | +9.22% | +47.55% | +19.94% |
| NVCT | Nuvectis Pharma, Inc. | $25.89 | +32.50% | +204.23% | +298.92% |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $9.37 | +7.09% | −23.76% | −3.50% |
| MNPR | Monopar Therapeutics Inc. | $110.82 | +0.44% | +67.88% | +264.30% |
| CTMX | CytomX Therapeutics, Inc. | $3.37 | +3.69% | −20.71% | +68.50% |
| EIKN | Eikon Therapeutics, Inc. | $12.55 | +27.02% | −16.33% | −16.33% |
| VSTM | Verastem, Inc. | $7.08 | +16.45% | −2.07% | −21.16% |
| SGMT | Sagimet Biosciences Inc. | $10.29 | +38.12% | +71.79% | +45.34% |
| CBIO | Crescent Biopharma, Inc. | $17.00 | +0.41% | +53.43% | +15.65% |
| ARVN | Arvinas, Inc. | $9.60 | +16.79% | −16.30% | +28.34% |
| DCTH | Delcath Systems, Inc. | $16.92 | +41.71% | +70.05% | +55.37% |
| PRLD | Prelude Therapeutics Incorporated | $6.59 | +69.41% | +141.39% | +418.90% |
| CCCC | C4 Therapeutics, Inc. | $4.20 | +16.99% | +117.62% | +66.01% |
| TOI | Starling Oncology Inc | $6.20 | +19.46% | +68.94% | +78.67% |
| RLMD | Relmada Therapeutics, Inc. | $4.59 | −11.73% | +5.03% | +635.58% |
| PBYI | Puma Biotechnology, Inc. | $9.32 | +16.65% | +61.53% | +86.77% |
| CMPX | Compass Therapeutics, Inc. | $2.53 | +21.63% | −51.06% | −16.23% |
| FENC | Fennec Pharmaceuticals Inc. | $11.71 | +14.69% | +52.47% | +35.38% |
| FHTX | Foghorn Therapeutics Inc. | $6.85 | +31.73% | +31.98% | +30.48% |
| GALT | Galectin Therapeutics Inc. | $3.99 | +18.05% | −1.48% | −0.25% |
| AGEN | Agenus Inc. | $8.36 | +36.38% | +158.82% | +90.43% |
| CATX | Perspective Therapeutics, Inc. | $3.29 | +16.67% | +17.92% | −4.91% |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $3.88 | −13.97% | +183.21% | +113.19% |
| STRO | Sutro Biopharma, Inc. | $21.44 | −10.70% | +95.62% | +155.24% |
| IMRX | Immuneering Corporation | $5.23 | +19.95% | −21.00% | −12.10% |
| BCYC | Bicycle Therapeutics plc | $4.39 | +11.14% | −34.28% | −38.34% |
| WHWK | Whitehawk Therapeutics, Inc. | $5.08 | +37.30% | +108.20% | +198.82% |
| ALXO | ALX Oncology Holdings Inc. | $2.00 | −0.99% | +73.91% | +81.82% |
| CGEN | Compugen Ltd. | $2.87 | +20.59% | +85.16% | +100.70% |
| MGNX | MacroGenics, Inc. Common Stock | $4.17 | +4.25% | +159.01% | +154.27% |
| GLSI | Greenwich LifeSciences, Inc. | $18.59 | +38.32% | −4.52% | +56.35% |
| PYXS | Pyxis Oncology, Inc. | $3.06 | +5.15% | +166.09% | +120.14% |
| IPHA | Innate Pharma S.A. | $2.27 | +28.10% | +24.73% | +1.34% |
| ADAG | Adagene Inc. | $3.82 | +8.22% | +107.61% | +62.55% |
| TARA | Protara Therapeutics, Inc. | $3.97 | −1.73% | −26.21% | +30.16% |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $11.31 | +24.56% | +43.71% | +14.36% |
| NBP | NovaBridge Biosciences | $1.93 | +8.43% | −54.80% | −59.96% |
| CHRS | Coherus Oncology, Inc. | $1.37 | −6.16% | 0.00% | +17.09% |
| MENS | Jyong Biotech Ltd. | $2.23 | −8.23% | −34.60% | −95.26% |
| CUE | Cue Biopharma, Inc. | $26.76 | −17.84% | +164.69% | +9.05% |
| MOLN | Molecular Partners AG | $4.38 | +9.36% | +3.79% | +3.91% |
| KZIA | Kazia Therapeutics Limited | $13.79 | +12.94% | +175.80% | +83.87% |
| OKUR | OnKure Therapeutics, Inc. | $3.85 | −4.94% | +30.07% | +36.77% |
| ASRT | Assertio Holdings Inc | $23.50 | 0.00% | +157.11% | +98.31% |
| INDP | Indaptus Therapeutics, Inc. | $1.10 | −46.32% | −60.04% | −84.51% |
| ADCT | ADC Therapeutics SA | $1.04 | −8.77% | −70.45% | −66.34% |
| HURA | TuHURA Biosciences, Inc. | $2.04 | −7.69% | +172.00% | −30.85% |
| LIXT | Nomad Power Solutions Inc | $4.15 | −6.74% | +8.07% | +26.14% |
| BDTX | Black Diamond Therapeutics, Inc. | $2.24 | +29.48% | −10.04% | −21.95% |
| ANIX | Anixa Biosciences, Inc. | $3.66 | +5.78% | +15.82% | +22.00% |
| GNLX | Genelux Corporation | $2.72 | −7.80% | −40.22% | −27.27% |
| NTHI | NeOnc Technologies Holdings, Inc. | $4.71 | +36.92% | −46.96% | −18.72% |
| ONCY | Oncolytics Biotech Inc. | $0.86 | +7.68% | −12.10% | −12.99% |
| AMAN | Amanat Acquisition Corp | $10.69 | +5.32% | +6.79% | +6.79% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.